Gamma Knife Dosimetric Differences, TMR 10 Versus Convolution Algorithm
Evaluation of Dosimetric Differences Between the TMR 10 and Convolution Algorithm for Gamma Knife Radiosurgery Planning
3 other identifiers
observational
100
1 country
1
Brief Summary
Gamma Knife Radiosurgery (GKR) is a well established treatment modality for brain tumors and functional disorders of the brain. It relies on mathematical algorithms to predict dose distribution and to calculate the dose at arbitrary points in the head. For the last 25 years, doses applied using Gamma Knife Radiosurgery have been calculated using a simple algorithm, called the Tissue Maximum Ratio algorithm (TMR). Dose planning using this algorithm, relies on a number of approximations to enable fast isodose computation during treatment planning. One of the most significant of these is the approximation of the head to water-equivalent density. The increased electron density of brain and bone (relative to water) and the near-zero density of air cavities in the skull may make significant perturbations to isodose and beam-on time calculations. With the advent of faster workstations, the effect of tissue in-homogeneities can finally be calculated in reasonable time during the treatment planning process; a newer, more modern algorithm known as convolution algorithm is now commercially available. It uses the values of density indicated in the CT scan to predict the dose distribution and is expected to more accurately calculate radiation dose, although it needs further investigation before clinical implementation. Inter- and intra-indication differences between the old and new algorithms need to be understood before this method can be confidently employed in a clinical setting. It is the aim of this study to understand the dosimetric differences between these dose calculation algorithms and to evaluate the implications of using the convolution algorithm for GKR. A large number of treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients. Beam-on-time, which is proportional to dose and a number of commonly used metrics for the targets such as coverage, selectivity, gradient index, and mean and maximum dose, will be estimated with both algorithms. Subgroup analysis will be done to assess whether any factor such as diagnosis, size of the head or location of the target could impact on the relative difference between the methods. The treatment plans will be compared and the potential implications on treatment planning will be elucidated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2013
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
February 16, 2015
CompletedFirst Posted
Study publicly available on registry
March 2, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2016
CompletedMarch 2, 2015
February 1, 2015
2 years
February 16, 2015
February 27, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Beam-on time (difference in the Beam-on-time of the treatment plans obtained using TMR 10 and convolution algorithm for each lesion treated)
The difference in the Beam-on-time of the treatment plans obtained using TMR 10 and convolution algorithm for each lesion treated will be the primary outcome of the study
Beam-on time obtained with the TMR 10 algorithm at the time of treatment (baseline) vs Beam-on time observed when the treatment is re-planned with the convolution algorithm, that being a few hours after the actual treatment is delivered (maximum 1 day)
Study Arms (1)
Research group
The group will consist of 100 patients (200 observations) receiving Gamma Knife treatment. Radiosurgery treatments will be re-planned using the convolution algorithm and compared to the TMR plans used to treat the patients.
Interventions
The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment. Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms.
Eligibility Criteria
The population of the study is all adult patients receiving treatment at the Gamma Knife Centre at Queen Square Radiosurgery Centre (QSRC). The sample will consist of the first 100 patients (200 observations) receiving Gamma Knife treatment in QSRC who accomplish all the inclusion and exclusion criteria and consent to participate in the study. This study does not involve group allocation or randomization of patients.
You may qualify if:
- Adult patients receiving Gamma Knife treatment for any diagnosis in the Gamma Knife centre at QSRC.
- The subject consents to participate in the study and consent to have a stereotactic non contrast CT scan of the brain after GKR has finished.
You may not qualify if:
- Inability to consent
- Younger than 18 years of age: Children are not eligible to give consent by themselves and at the moment only adults are being treated at the QSRC.
- Patient is not suitable for CT scan: There are no absolute clinical contraindications for CT scan. However, for the purpose of the study, pregnancy is considered an absolute contraindication. Claustrophobia or anxiety disorders are considered a relative contraindication; however, this is more likely to affect the subject ability to tolerate Gamma Knife treatment and MRI scanning, which would make the patient not eligible or the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University College, Londonlead
- University College London Hospitalscollaborator
Study Sites (1)
The Gamma Knife Centre at Queen Square
London, London,City of, WC1N 3BG, United Kingdom
Study Officials
- STUDY CHAIR
Neil Kitchen
The National Hospital for Neurology and Neurosurgery
Central Study Contacts
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 16, 2015
First Posted
March 2, 2015
Study Start
October 1, 2013
Primary Completion
October 1, 2015
Study Completion
October 1, 2016
Last Updated
March 2, 2015
Record last verified: 2015-02